What Aubra Eq Treats: Main Uses and Benefits

Aubra Eq is relevant in clinical settings for two main therapeutic domains: contraception and symptom management related to physical discomfort.

This medication is commonly used across conditions presenting with acute episodes related to the reproductive cycle. It is considered relevant for managing symptoms that interfere with daily comfort. The primary application helps with pregnancy prevention for women of reproductive potential.

The medication is generally applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as severe menstrual cramps, abnormally heavy or prolonged menstrual bleeding, and irregular cycle timing. This use falls within the domain of long-term, planned reproductive management. It supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

---

Quick Therapeutic Facts

Condition Category	Primary Benefit Focus
Fertility Management	Helps with pregnancy prevention and supports planned reproductive management.
Symptom Management	Assists in managing symptoms related to severe menstrual cramps and heavy bleeding.
Cycle Regulation	Supports the patient with the benefit of scheduled monthly cycles.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Aubra Eq?

The population eligibility for Aubra Eq (Levonorgestrel and Ethinyl Estradiol) is strictly defined by regulatory contraindications to minimize the risk of serious cardiovascular events and thromboembolism.

Absolute Contraindications (Do Not Use)

Official labeling mandates that Aubra Eq must not be used by individuals with specific high-risk conditions. This includes:

• Smoking Status and Age: Females over 35 years of age who smoke.
• Thrombotic History: Current or history of deep vein thrombosis, pulmonary embolism, stroke, coronary artery disease, or other high-risk thrombotic diseases.
• Cancer: Current or history of breast cancer or other estrogen-sensitive cancers.
• Liver Disease: Liver tumors (benign or malignant) or severe liver disease, including acute viral hepatitis or decompensated cirrhosis.
• Pregnancy: The medication is absolutely contraindicated during pregnancy.
• Comorbidities: Uncontrolled hypertension, diabetes mellitus with vascular disease, or migraine headaches with aura.

Specific Population Eligibility

• Age: Approved for post-menarchal females seeking pregnancy prevention; use is not established in pre-menarchal females and is not indicated for post-menopausal women.
• Lactation: Use is generally not recommended for nursing mothers.

The official interaction profile for Aubra Eq (Levonorgestrel and Ethinyl Estradiol) is defined by its pharmacokinetic effects on other substances and the influence of co-administered drugs on its hormone levels.

---

Interaction Classifications

A major contraindication exists for co-administration with specific Hepatitis C combination regimens, including ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented risk of liver enzyme elevation. A mandatory timing constraint also requires the product be discontinued for at least four weeks before and through two weeks after major surgery due to the risk of thromboembolism.

---

Official Interaction Statements

Clinically significant interactions occur with enzyme-inducing medicines, such as the anticonvulsants Phenytoin and Carbamazepine, and the antibiotic Rifampin. These substances may decrease the systemic exposure of the contraceptive hormones, potentially reducing effectiveness. Conversely, Aubra Eq can interfere with the clearance of other drugs, leading to increased plasma concentrations for certain agents, including Lamotrigine, Theophylline, and Acetaminophen. Interactions also exist with specific non-medicinal products; the herbal product St. John's Wort and certain preparations of Grapefruit Juice are documented to alter hormone exposure.

This structure highlights substances that both compromise contraceptive efficacy and those that may lead to altered exposure of co-administered medicines.

How Aubra Eq Works

Aubra Eq is a combination hormonal contraceptive that acts via several molecular and physiological pathways. The core mechanism is the suppression of gonadotropins (Luteinizing Hormone and Follicle-Stimulating Hormone) from the pituitary gland, which directly causes the inhibition of ovulation .

The ethinyl estradiol component acts as an estrogen receptor agonist and induces Sex Hormone Binding Globulin (SHBG) synthesis in the liver. The levonorgestrel component binds to progesterone and androgen receptors to amplify the central suppression of gonadotropins. In addition, the progestin component increases the viscosity and quantity of the cervical mucus, which physically impedes sperm migration into the uterus. The combination also induces local morphological changes to the endometrium, specifically stromal pseudodecidualization and glandular atrophy, thereby reducing the probability of implantation.

How to Use Aubra Eq: Official Administration Guidelines

Aubra Eq (levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg tablets) is administered through the oral route as a monophasic tablet. Its use follows a strict, repeating 28-day cyclic dosing pattern as prescribed in official administration guidelines.

---

Standard Dosing and Schedule

Instruction	Detail
Daily Dose	One tablet must be taken once daily for 28 consecutive days.
Timing	The tablet must be taken at the same time each day to maintain the 24-hour interval.
Tablet Sequence	The regimen involves 21 days of active hormone-containing tablets, followed by 7 days of inactive (placebo) tablets.
Cycle Repetition	The new 28-day course begins immediately after the last inactive tablet, with no gap between packs.

---

Administration Protocols

Administration may be initiated using one of two methods: the Day 1 Start (beginning on the first day of the menstrual period) or the Sunday Start (beginning on the first Sunday after the start of menstruation). The tablets must always be ingested in the order directed on the blister packaging.

Regarding the intake context, the tablets may be taken with or after the evening meal or at bedtime, which is a consideration for administration but does not affect the drug's intended action. The use of a non-hormonal back-up method is specified as a requirement for the first 7 consecutive days if the regimen is initiated later than Day 1 of the menstrual cycle.

Aubra Eq: Recent Clinical Evidence

---

Research exploring prevention of pregnancy

Research has evaluated Aubra Eq in studies focusing on preventing pregnancy. The primary evidence comes from research settings where the product was studied for prevention of pregnancy, typically involving large groups of women. These studies primarily focused on outcomes reflecting daily functioning or activity level related to fertility and monitoring pregnancy rates over defined time intervals.

When was observed in these settings, the data show patterns related to low rates of unintended pregnancy. The findings describe patterns observed in the studies conducted among women using the product, and in these studies, the product was associated with the prevention of pregnancy in the observed populations. The research contributes to the broader understanding of these patterns.

However, the long-term effects are not fully established, and follow-up durations were limited in some of the research. Evidence is limited for certain specific populations, and results apply only to the populations studied.

---

Research exploring symptom patterns in conditions characterized by fluctuating or episodic manifestations

Aubra Eq was studied for its potential association with changes in conditions characterized by fluctuating or episodic manifestations, such as those related to the menstrual cycle. Research examined how individuals reported their experience over the study period.

For some individuals in the observed research, the findings indicate that the use of this product was associated with more predictable timing of menstrual bleeding. Studies describe changes in outcomes related to physical discomfort and bleeding heaviness for some users. This research provides insight into short-term changes in these patient-reported outcomes describing perceived discomfort.

While these patterns were observed, the certainty remains low for generalizing these effects to all individuals, as subgroup findings are uncertain. The evidence quality varies across studies for these secondary outcomes.

---

Research exploring outcomes linked to inflammatory or irritative states

Research examined the product's use in contexts involving outcomes linked to inflammatory or irritative states of the skin, particularly acne. In some studies, the product may be associated with observed changes in skin appearance over time. This research highlights changes measured during the study period and helps contextualize how patients reported their experience.

However, the sample sizes were modest in some of these studies, and follow-up durations were limited. This means that long-term effects are not fully established regarding the consistency of these patterns over many years. Because data for certain groups remain insufficient, research does not determine whether an individual will respond similarly to the group patterns described in the evidence.

Key Studies & References

1. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial
2. Aubra EQ (Levonorgestrel and Ethinyl Estradiol Tablets USP) 0.1 mg/0.02 mg Prescribing Information
3. ACOG Practice Bulletin No. 110: Management of Menstrual Cycle-Related Symptoms
4. Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception (NCT00248963)

Common questions about Aubra Eq (FAQ)

Q: What is Aubra Eq used for?

A: Aubra Eq is a combination birth control pill approved to help prevent pregnancy. It contains two types of hormones, ethinyl estradiol (an estrogen) and levonorgestrel (a progestin). The primary way it works is by stopping the release of an egg (ovulation) and by changing the cervical mucus and uterine lining.

Q: How do I start taking Aubra Eq?

A: The decision on how and when to start Aubra Eq should be made after consulting with a healthcare professional. They can help you determine the appropriate start time, such as a Sunday start or a day-one start, based on your medical history and cycle. You should always follow the specific instructions provided by your doctor and the patient information leaflet.

Q: What should I do if I miss a pill?

A: The instruction for a missed pill is complex and depends on the number of pills missed and where you are in your cycle (week 1, 2, or 3). It is essential to refer to the official patient information leaflet or product labeling that comes with your prescription for detailed, specific instructions on what steps to take, as this information may vary.

Q: Does Aubra Eq protect against sexually transmitted infections (STIs)?

A: No, hormonal birth control like Aubra Eq does not offer protection against HIV/AIDS or any other sexually transmitted infections. Only barrier methods, such as condoms, can help reduce the risk of transmission.

How to Store and Dispose of Aubra EQ

Aubra EQ (levonorgestrel and ethinyl estradiol tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product should be kept in its original closed container and be protected from both light and moisture. The official labeling instructs that the medicine must not be frozen and should be kept out of the reach of children.

Disposal Requirements

Expired or unused tablets should be disposed of according to local waste regulations. The medication is not recommended to be flushed down the toilet. Preferred methods include authorized drug take-back programs or following the safe household disposal procedure of mixing the tablets with an undesirable substance and sealing the mixture before discarding.